Business context and reporting period
This is Eyenovia, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2020; the request metadata names Hyperion DeFi, Inc., which does not match the company identified in the filing. Eyenovia is a clinical-stage ophthalmic biopharmaceutical company developing microdose therapies delivered with its Optejet technology. It has no product revenue and remains in research and development.
Financial results and position
- Revenue and margins: No product revenue was reported. The company reported operating expenses of $5.47 million and an operating loss of $5.47 million; gross margin is not applicable given the absence of revenue.
- Profit: Net loss was $5.45 million, or $0.31 per basic and diluted share, compared with $5.93 million, or $0.50 per share, in Q1 2019. Weighted-average shares rose to 17.31 million from 11.92 million.
- Expenses: R&D expense declined 9.3% to $3.63 million; G&A expense declined 5.5% to $1.84 million.
- Cash flow: Operating cash use was $5.92 million, versus $5.90 million in Q1 2019. Investing cash use was $0.09 million. Financing provided $5.52 million, principally from the March private placement. Cash decreased $0.50 million to $13.66 million.
- Liquidity and debt: Working capital was $12.0 million; current assets were $14.52 million and current liabilities $2.54 million. Total liabilities were $2.58 million, including a $0.42 million short-term insurance-financing note; the note’s original principal was $475,216. Stockholders’ equity was $12.33 million.
- Accumulated deficit: $63.12 million. Cash was approximately $13.7 million at quarter-end.
Material changes versus the prior comparable period
- Net loss narrowed by about $0.48 million, while operating cash use was broadly unchanged.
- Lower clinical and non-clinical spending, partly attributed to COVID-19 disruptions, and lower stock-based compensation drove the R&D decrease. Personnel and supplies costs increased.
- G&A decreased modestly, reflecting lower travel and professional fees, partly offset by increased salaries, marketing, rent, utilities, and insurance.
- The March 2020 private placement issued 2.68 million shares plus warrants and generated approximately $5.45 million net proceeds. Common shares outstanding increased from 17.10 million at year-end to 19.78 million at March 31.
Outlook, risks, contingencies, and unusual items
- Going concern: Management states that substantial doubt exists about the company’s ability to continue as a going concern for at least one year after issuance of the financial statements. Continued operations depend on raising additional capital; without it, R&D and other costs may need to be reduced. No specific financing guidance is provided.
- Development outlook: COVID-19 delayed enrollment and trial initiation for MicroPine and the planned Phase III MicroLine VISION trials. Eyenovia said it remained on track to file a MicroStat NDA in 2020, while noting the pandemic could affect timing. It had completed MicroStat Phase III trials and reported positive results. The company has deferred MicroProst and MicroTears development.
- Subsequent events: On April 8, 2020, Eyenovia amended its Senju license, allowing certain products to be licensed to a third party in specified Asian territories if a license is executed by April 8, 2021; payments to Senju include minimum payment obligations described as at least a high-seven-figure amount. On May 8, the company received a $463,353 PPP loan at 1% interest, maturing May 3, 2022; forgiveness is not assured.
- Other matters: The filing reports no legal proceedings and no material off-balance-sheet arrangements. It discloses related-party consulting, facility lease, and R&D vendor relationships. The company reported effective disclosure controls as of quarter-end.
Important facts for investors to verify
- Confirm the intended issuer: the supplied metadata says Hyperion DeFi, Inc., but the filing is for Eyenovia, Inc.
- Assess cash runway and access to additional financing in light of the explicit going-concern warning and ongoing operating cash burn.
- Track COVID-19 effects on clinical trial enrollment, MicroStat NDA timing, and development timelines.
- Review dilution and potential warrant exercises from the March financing, alongside future capital needs.
- Verify the terms, permitted uses, and potential forgiveness of the PPP loan, and the obligations and deadlines under the Senju license amendment.